Genetic Technologies Limited (GENE)
USD 0.77
(0.0%)
USD 0.77
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -6.53 Million AUD | 37.24% |
| 2023 | -10.41 Million AUD | -131.06% |
| 2022 | -4.29 Million AUD | 39.25% |
| 2021 | -7.06 Million AUD | -16.1% |
| 2020 | -6.08 Million AUD | -1.43% |
| 2019 | -5.99 Million AUD | -0.35% |
| 2018 | -5.97 Million AUD | 25.24% |
| 2017 | -7.99 Million AUD | 5.48% |
| 2016 | -8.45 Million AUD | -4.44% |
| 2015 | -8.09 Million AUD | 13.23% |
| 2014 | -9.33 Million AUD | -2.47% |
| 2013 | -9.1 Million AUD | -54.2% |
| 2012 | -5.9 Million AUD | -711.78% |
| 2011 | 965.55 Thousand AUD | 112.57% |
| 2010 | -7.68 Million AUD | 6.75% |
| 2009 | -8.23 Million AUD | -323.4% |
| 2008 | -1.94 Million AUD | -25.09% |
| 2007 | -1.55 Million AUD | 74.78% |
| 2006 | -6.16 Million AUD | 20.58% |
| 2005 | -7.76 Million AUD | -1.45% |
| 2004 | -7.65 Million AUD | -77.0% |
| 2003 | -4.32 Million AUD | 51.28% |
| 2002 | -8.87 Million AUD | -158.76% |
| 2001 | -3.43 Million AUD | -22.31% |
| 2000 | -2.8 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.58 Million AUD | 43.66% |
| 2024 FY | -12.58 Million AUD | -26.88% |
| 2024 Q2 | -5.16 Million AUD | 0.0% |
| 2024 Q3 | -1.73 Million AUD | 66.4% |
| 2024 Q4 | -1.73 Million AUD | 0.0% |
| 2023 FY | -9.91 Million AUD | -131.06% |
| 2023 Q1 | -2.69 Million AUD | 37.51% |
| 2023 Q3 | -2.51 Million AUD | 53.4% |
| 2023 Q4 | -4.58 Million AUD | -82.4% |
| 2023 Q2 | -5.39 Million AUD | -100.0% |
| 2022 Q3 | -1.82 Million AUD | 63.28% |
| 2022 Q2 | -4.97 Million AUD | -155.51% |
| 2022 Q4 | -4.31 Million AUD | -136.28% |
| 2022 FY | -4.29 Million AUD | 39.25% |
| 2022 Q1 | -1.94 Million AUD | 53.47% |
| 2021 Q2 | -4.44 Million AUD | -141.08% |
| 2021 Q1 | -1.84 Million AUD | 54.68% |
| 2021 FY | -7.06 Million AUD | -16.1% |
| 2021 Q4 | -4.18 Million USD | -124.05% |
| 2021 Q3 | -1.86 Million AUD | 58.0% |
| 2020 Q4 | -4.06 Million AUD | -71.78% |
| 2020 FY | -6.08 Million AUD | -1.43% |
| 2020 Q2 | -3.08 Million AUD | -133.91% |
| 2020 Q3 | -2.36 Million AUD | 23.3% |
| 2020 Q1 | -1.32 Million AUD | 61.1% |
| 2019 Q1 | -1.55 Million AUD | -2.91% |
| 2019 FY | -5.99 Million AUD | -0.35% |
| 2019 Q2 | -1.55 Million AUD | 0.0% |
| 2019 Q3 | -1.95 Million AUD | -25.44% |
| 2019 Q4 | -3.39 Million USD | -73.83% |
| 2018 Q4 | -1.51 Million AUD | 0.0% |
| 2018 FY | -5.97 Million AUD | 25.24% |
| 2018 Q2 | -1.68 Million AUD | 0.0% |
| 2018 Q1 | -1.68 Million AUD | 13.6% |
| 2018 Q3 | -1.51 Million AUD | 10.46% |
| 2017 Q4 | -1.95 Million AUD | 0.0% |
| 2017 Q3 | -1.95 Million AUD | 4.28% |
| 2017 Q2 | -2.04 Million AUD | 0.0% |
| 2017 Q1 | -2.04 Million AUD | 7.99% |
| 2017 FY | -7.99 Million AUD | 5.48% |
| 2016 Q4 | -2.21 Million AUD | 0.0% |
| 2016 Q2 | -2.02 Million AUD | 0.0% |
| 2016 Q1 | -2.02 Million AUD | 3.42% |
| 2016 Q3 | -2.21 Million AUD | -9.5% |
| 2016 FY | -8.45 Million AUD | -4.44% |
| 2015 FY | -8.09 Million AUD | 13.23% |
| 2015 Q4 | -2.09 Million AUD | 0.0% |
| 2015 Q3 | -2.09 Million AUD | 25.93% |
| 2015 Q2 | -2.83 Million AUD | 0.0% |
| 2015 Q1 | -2.83 Million AUD | -15.75% |
| 2014 Q4 | -2.44 Million AUD | 0.0% |
| 2014 FY | -9.33 Million AUD | -2.47% |
| 2014 Q2 | -2.65 Million AUD | 0.0% |
| 2014 Q1 | -2.65 Million AUD | 3.7% |
| 2014 Q3 | -2.44 Million AUD | 7.86% |
| 2013 Q1 | -1.9 Million AUD | 0.0% |
| 2013 FY | -9.1 Million AUD | -54.2% |
| 2013 Q3 | -2.75 Million AUD | -44.95% |
| 2013 Q2 | -1.9 Million AUD | 0.0% |
| 2013 Q4 | -2.75 Million AUD | 0.0% |
| 2012 FY | -5.9 Million AUD | -711.78% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 Q2 | - AUD | 0.0% |
| 2011 FY | 965.55 Thousand AUD | 112.57% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | -7.68 Million AUD | 6.75% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | -8.23 Million AUD | -323.4% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 FY | -1.94 Million AUD | -25.09% |
| 2008 Q1 | 4.42 Million AUD | 149.16% |
| 2008 Q2 | -66.52 Thousand AUD | -101.51% |
| 2008 Q4 | -14.35 Million AUD | -316.43% |
| 2008 Q3 | 6.63 Million AUD | 10067.03% |
| 2007 Q3 | 4.24 Million AUD | 267.61% |
| 2007 Q4 | -8.99 Million AUD | -312.04% |
| 2007 FY | -1.55 Million AUD | 74.78% |
| 2007 Q2 | -2.52 Million AUD | -193.41% |
| 2007 Q1 | 2.7 Million AUD | 119.52% |
| 2006 Q3 | 2.56 Million AUD | 278.52% |
| 2006 Q4 | -13.87 Million AUD | -640.11% |
| 2006 Q1 | 3.37 Million AUD | 118.48% |
| 2006 FY | -6.16 Million AUD | 20.58% |
| 2006 Q2 | -1.43 Million AUD | -142.63% |
| 2005 FY | -7.76 Million AUD | -1.45% |
| 2005 Q4 | -18.26 Million AUD | -614.47% |
| 2005 Q1 | 3.76 Million AUD | 0.0% |
| 2005 Q2 | -186.77 Thousand AUD | -104.96% |
| 2005 Q3 | 3.55 Million AUD | 2001.27% |
| 2004 FY | -7.65 Million AUD | -77.0% |
| 2003 FY | -4.32 Million AUD | 51.28% |
| 2002 FY | -8.87 Million AUD | -158.76% |
| 2001 FY | -3.43 Million AUD | -22.31% |
| 2000 FY | -2.8 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 93.285% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 40.318% |
| Aspira Women's Health Inc. | -18.85 Million USD | 65.324% |
| Biodesix, Inc. | -41.34 Million USD | 84.188% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -152.051% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 18.011% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 18.011% |
| Bionano Genomics, Inc. | -215.24 Million USD | 96.963% |
| CareDx, Inc | -101.9 Million USD | 93.585% |
| Check-Cap Ltd. | -19.28 Million USD | 66.106% |
| Castle Biosciences, Inc. | -67.97 Million USD | 90.383% |
| DarioHealth Corp. | -56.18 Million USD | 88.366% |
| Exact Sciences Corporation | -215.01 Million USD | 96.96% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 91.007% |
| Guardant Health, Inc. | -564.72 Million USD | 98.842% |
| ICON Public Limited Company | 956.15 Million USD | 100.684% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 100.596% |
| Illumina, Inc. | -1.06 Billion USD | 99.388% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | 36.429% |
| iSpecimen Inc. | -11.16 Million USD | 41.472% |
| Standard BioTools Inc. | -76.6 Million USD | 91.466% |
| MDxHealth SA | -27.32 Million USD | 76.078% |
| 23andMe Holding Co. | -321.35 Million USD | 97.966% |
| Medpace Holdings, Inc. | 336.82 Million USD | 101.941% |
| Myriad Genetics, Inc. | -123.7 Million USD | 94.715% |
| Mainz Biomed B.V. | -26.64 Million USD | 75.465% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | 37.864% |
| NeoGenomics, Inc. | -107.73 Million USD | 93.932% |
| Neogen Corporation | 58.66 Million USD | 111.144% |
| Inotiv, Inc. | -81.46 Million USD | 91.975% |
| Natera, Inc. | -446.24 Million USD | 98.535% |
| OpGen, Inc. | -15.68 Million USD | 58.331% |
| OPKO Health, Inc. | -157.02 Million USD | 95.837% |
| Psychemedics Corporation | -2.92 Million USD | -123.799% |
| Prenetics Global Limited | -52.51 Million USD | 87.551% |
| Prenetics Global Limited | -52.51 Million USD | 87.551% |
| Precipio, Inc. | -7.62 Million USD | 14.21% |
| Personalis, Inc. | -109.93 Million USD | 94.054% |
| RadNet, Inc. | 98.69 Million USD | 106.623% |
| Sera Prognostics, Inc. | -39.82 Million USD | 83.584% |
| Sotera Health Company | 276.69 Million USD | 102.363% |
| Neuronetics, Inc. | -30.55 Million USD | 78.605% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -50.418% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -50.418% |
| Trinity Biotech plc | -27.04 Million USD | 75.829% |
| T2 Biosystems, Inc. | -49.66 Million USD | 86.837% |
| Twist Bioscience Corporation | -220.83 Million USD | 97.04% |
| Exagen Inc. | -22.83 Million USD | 71.375% |